HIV 2011 - 9th European Wshp. on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance

Abstracts should contain the following four components.

Background: a concise statement of the issue under investigation or a hypothesis;
Material & Methods: the experimental methods used (including the statistical analyses employed);
Results: specific findings (promises such as "to be completed" or "to be presented" are not acceptable); and
Conclusions: a summary of findings that are supported by your results (statistical analyses used to support the conclusions, where appropriate, should be included; concluding statements such as "the results will be discussed" are not acceptable).

Please note that abstracts cannot be accepted if tables or graphs are included.
The maximum word count for the abstract body is 500 words.

Abstracts are considered official communications to the conference and will be treated confidentially. For those abstracts that are accepted, submitters agree to attend the meeting and present their abstracts as scheduled.

Abstract submission
Authors can submit their abstracts electronically from 1 December 2010 until 28 January 2011 using the button on the right. This will direct you to the appropriate webpage.
Please follow the step-by-step directions to upload the abstract file. To ensure that your abstract retains any special characters or formatting, the abstract must be in Microsoft Word format.

Categories for abstract submission
For purposes of review and programming, abstracts are divided into topical categories related to Antiviral Drug Resistance. Selection of the most appropriate category is important as it determines who will review your abstract. The Program Committee reserves the right to reassign your abstract to a more appropriate category.

- Clinical case (HIV, HCV, HBV or Inf.)
- Clinical Implications of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Mechanism of Antiviral Drug Resistance (Hepatitis B, Hepatitis C and HIV)
- Novel Diagnostic Technologies & Approaches
- Novel Therapeutic options for Hepatitis B, Hepatitis C or HIV
- Resistance to Antiviral Drugs (Hepatitis B, Hepatitis C and HIV)
- Spread of Drug Resistance
- Therapeutic Challenges in Resource-limited settings
- Treatment Strategies in Co-infected Patients
- Treatment Strategies in Hepatitis infected Patients
- Treatment Strategies in HIV infected Patients
- Viral Evolution & Genetic variation

Notification of abstract acceptance and presentation format
Notifications of acceptance and format of presentation (oral or poster) will be e-mailed to submitting authors approximately two weeks after the abstract submission deadline has been reached. It is the responsibility of the corresponding/presenting author to inform all co-authors of the abstract’s status. Please notify the Conference Secretariat if you have not received a notification by the second week of February.

If your abstract is accepted, one author is required to register for the conference and present the paper as scheduled. Guidelines for preparing your oral and/or poster presentations will be sent after your abstract has been accepted.

Abstract publication
Accepted abstracts will be published in the Final Program and Abstract Book which, will be distributed during the conference. In addition, all abstracts will be published in the journal Reviews in Antiviral Therapy & Infectious Diseases.
Please note that the conference secretariat cannot be held responsible for any typing or language errors in the submitted abstracts as only the format of the abstracts will be changed and not the content.